Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Judson Cook

Neurological Surgery Cheyenne, WY Medical Doctor

NPI 1386603553 CMS profile 62695

1950 Bluegrass Cir, Ste 170, Cheyenne, WY 82009

Open in the dashboard

General payments

$25,025

436 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Judson Cook of Cheyenne, WY is reported in the CMS Open Payments database as having received $25,025 across 436 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,845 72
2024 General $1,863 59
2023 General $3,581 57
2022 General $1,917 61
2021 General $3,996 64
2020 General $3,691 26
2019 General $3,132 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Judson Cook
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Judson Cook were reported at $6,845. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Judson Cook Neurological Surgery median Middle half National median
2019 $3,132 $582 $138–$3,006 $163
2020 $3,691 $294 $76–$2,174 $114
2021 $3,996 $387 $105–$2,432 $132
2022 $1,917 $542 $139–$2,989 $149
2023 $3,581 $534 $145–$2,697 $160
2024 $1,863 $574 $155–$3,046 $164
2025 $6,845 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $7,174 238 payments
  2. Abbott Laboratories $6,515 55 payments
  3. Stryker Corporation $5,244 28 payments
  4. Nvision Biomedical Technologies, Inc. $3,045 3 payments
  5. SI-BONE, Inc. $1,580 58 payments
  6. Medtronic, Inc. $436 19 payments
  7. Providence Medical Technology, Inc. $133 1 payment
  8. DePuy Synthes Sales Inc. $102 3 payments
  9. Orthofix Medical, Inc. $96 5 payments
  10. Highridge Medical LLC $93 1 payment
  11. Other $606 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,473 420 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $4,800 1 payment
  3. Travel and Lodging $4,502 11 payments
  4. Consulting Fee $4,250 4 payments
Products named General payments · program years 2019–2025
  1. PROCLAIM $5,114 6 payments
  2. General - Pain Management General - Pain Management_NMD $1,662 61 payments
  3. TRITANIUM $1,489 6 payments
  4. EVEREST SPINAL SYSTEM $1,439 11 payments
  5. General Therapies $1,000 1 payment
  6. GENERAL PAIN MANAGEMENT $899 41 payments
  7. IFUSE IMPLANT $488 20 payments
  8. Proclaim Family of SCS IPGs $398 29 payments
  9. GENERAL - PAIN MANAGEMENT Pain Management $388 14 payments
  10. SPECTRA WAVEWRITER $310 12 payments
  11. Other $4,179 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

273

Median for Neurosurgery: 83

Drug cost

$4,866

Median for Neurosurgery: $872

Branded share of claims

56%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 92 $1,430
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 47 $1,169
Oxycodone Hcl Generic 29 $807
Morphine Sulfate Er Morphine Sulfate Brand 14 $569
Methocarbamol Generic 15 $344
Hydromorphone Hcl Generic 44 $270
Gabapentin Generic 18 $167
Doxycycline Hyclate Generic 14 $110

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$166,646

Medicare's payments for the services billed

Medicare patients

147

Average age 72

Services billed

642

84 women, 63 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 37%
Depression 37%
Ischemic heart disease 31%
Chronic kidney disease 24%
Osteoporosis 22%
COPD 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

436 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record